We are live on ! Find out more
EUCRW

Eucrates Biomedical Acquisition Corp. Warrant
EUCRW

Delisted

EUCRW was delisted on the 26th of April, 2023.

Back to rankings

17 hedge funds and large institutions have $1.91M invested in Eucrates Biomedical Acquisition Corp. Warrant in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

11% less funds holding

Funds holding: 19 → 17 (-2)

16% less capital invested

Capital invested by funds: $2.27M → $1.91M (-$357K)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
17
Holders Change
-2
Holders Change %
-10.53%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AA
AQR Arbitrage
Connecticut
+$39.3K
2
Jane Street
Jane Street
New York
+$34

Top Sellers

Rank Fund Capital Flow
1
EPM
Equitec Proprietary Markets
Illinois
-$9K
2
EAM
Exos Asset Management
New York
-$4K
3
PAM
Panagora Asset Management
Massachusetts
-$3K
4
UBS Group
UBS Group
Switzerland
-$655
Name Holding Trade Value Shares
Change 		Change in
Stake
EC
1
EcoR1 Capital
California
$652K – – –
RCM
2
Radcliffe Capital Management
Pennsylvania
$326K – – –
BlackRock
3
BlackRock
New York
$221K – – –
6CM
4
683 Capital Management
New York
$142K – – –
ACM
5
Altium Capital Management
New York
$107K – – –
GPCM
6
Granite Point Capital Management
Massachusetts
$107K – – –
CH
7
CVI Holdings
Delaware
$85K – – –
MIM
8
Monashee Investment Management
Massachusetts
$71K – – –
KCM
9
Kingdon Capital Management
New York
$48K – – –
AA
10
AQR Arbitrage
Connecticut
$33K +$39.3K +45,832 New
CAC
11
Cowen and Company
New York
$27K – – –
RCM
12
Rivernorth Capital Management
Florida
$27K – – –
SCM
13
Suvretta Capital Management
New York
$24K – – –
Jane Street
14
Jane Street
New York
$19K +$34 +40 +0.2%
T. Rowe Price Associates
15
T. Rowe Price Associates
Maryland
$18K – – –
UBS Group
16
UBS Group
Switzerland
$1K -$655 -763 -39%
Morgan Stanley
17
Morgan Stanley
New York
$1K – – –
EPM
18
Equitec Proprietary Markets
Illinois
– -$9K -8,716 Closed
EAM
19
Exos Asset Management
New York
– -$4K -3,495 Closed
PAM
20
Panagora Asset Management
Massachusetts
– -$3K -3,321 Closed

EUCRW Hedge Fund Activity: Q3 2021 in Review

17 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) for Q3 2021, worth a combined $1.91M — down 16% from $2.27M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of EUCRW and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.

The largest buyer was AQR Arbitrage, opening a new position worth an estimated $39.3K. The largest seller was Equitec Proprietary Markets, exiting entirely with an estimated $9K sold.

  • 17 institutional investors held Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) as of Q3 2021, down from 19 in Q2 2021.
  • Funds reported $1.91M of Eucrates Biomedical Acquisition Corp. Warrant stock for Q3 2021, down 16% quarter-over-quarter.
  • 1 fund opened new Eucrates Biomedical Acquisition Corp. Warrant positions in Q3 2021 and 3 closed out, a net change of -2 holders.
  • The largest Eucrates Biomedical Acquisition Corp. Warrant buyer in Q3 2021 was AQR Arbitrage, an estimated $39.3K added.
  • The largest Eucrates Biomedical Acquisition Corp. Warrant seller in Q3 2021 was Equitec Proprietary Markets, an estimated $9K sold.

Based on aggregated 13F filings for Q3 2021.